Morgan Stanley downgrades Aardvark Therapeutics stock rating on FDA hold
Morgan Stanley downgrades Aardvark Therapeutics stock rating on FDA hold
Morgan Stanley downgrades Aardvark Therapeutics stock rating on FDA hold
Latest in Markets
-
HSBC to redeem CNH2.75 billion notes due 2027 on June 29
-
Goldman Sachs upgrades ORIC Pharmaceuticals stock rating to buy
-
BofA raises Legence stock price target to $105 on strong Q1 results
-
Evercore ISI initiates Devon Energy stock with In Line rating
-
Exclusive-Schroders to exit wholly-owned China fund management unit, sources say
-
America’s most powerful CEOs don’t have much to show from their China trip so far
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.